Trials / Completed
CompletedNCT00262236
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 693 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-12-06
- Last updated
- 2016-11-18
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00262236. Inclusion in this directory is not an endorsement.